You are here

Pfizer Announces Executive Leadership Team

Tuesday, October 9, 2018 - 9:05am
EDT

Pfizer Inc. (NYSE:PFE) today announced its executive team that will
report to Albert Bourla, incoming Chief Executive Officer, coincident
with the commencement of his new role effective January 1, 2019.

“We are at a pivotal moment in Pfizer’s history, with Ian Read having
positioned the company with a strong portfolio of marketed products, a
deep pipeline and the clear potential to accelerate our revenue growth,”
said Bourla. “Given this opportunity to realize this accelerated growth
potential, we are creating an executive team that has a proven record of
success, an unwavering commitment to the patients we serve, and a clear
value creation initiative. I look forward to working with these
outstanding leaders to achieve the full potential of our pipeline and
deliver our next stage of growth.”

Frank D’Amelio – Chief Financial Officer and Executive Vice President,
Global Supply and Business Operations, will also assume the leadership
for our manufacturing operations, Pfizer Global Supply (PGS).

Mikael Dolsten – Global President, Worldwide Research and Development,
and Medical, will also assume oversight of the Chief Medical Officer’s
role.

Michael Goettler - Global President, Established Medicines. As
previously announced Michael will lead the Established Medicines
business that will operate as an autonomous, stand-alone unit within
Pfizer.

Angela Hwang - Group President, Pfizer Innovative Medicines, will become
the Group President of Pfizer’s science-based Innovative business
responsible for the entire portfolio of innovative medicines.

Rady Johnson – Executive Vice President, Chief Compliance, Quality and
Risk Officer, will continue in his role as the Company’s Chief
Compliance Officer.

Doug Lankler – Executive Vice President, General Counsel, will continue
in his role as the company’s General Counsel.

Freda Lewis-Hall – Executive Vice President, Chief Patient Officer, will
assume a new role as Pfizer’s Chief Patient Officer, deploying the
resources of the company to advocate on behalf of all patients who rely
on Pfizer to deliver new therapies and vaccines.

Rod MacKenzie – Executive Vice President, Chief Development Officer,
will expand his responsibilities to include Pfizer’s regulatory affairs
function in addition to all late stage development activities.

Dawn Rogers – Executive Vice President, Chief Human Resources Officer,
will continue to lead the Human Resources team.

Sally Susman – Executive Vice President, Chief Corporate Affairs
Officer, will continue to lead the Corporate Affairs function.

John Young - Group President, Chief Business Officer, will assume a new
role, responsible for strategy, business development, portfolio
management and valuation activities; business analytics; global
commercial operations; and Patient and Health Impact, among others.
Pfizer’s Consumer Healthcare business will also report to John.

Given the growing strategic importance of deploying digital technologies
in research, discovery and business processes, Pfizer is appointing a
Chief Digital Officer responsible for creating and implementing a
strategy that accelerates and improves our digital capabilities so we
can deliver more value to patients. Lidia Fonseca will join Pfizer’s
Executive Leadership Team in January 2019, as Executive Vice President,
Chief Digital and Technology Officer. She is currently the Chief
Information Officer and Senior Vice President at Quest Diagnostics.
Previously, she served as SVP at Laboratory Corporation of America,
Executive Vice President of Global Operations and Technology at Synarc
Incorporated, and held several positions of increasing responsibility at
Philips Healthcare.

Executive Vice President and President, PGS, Dr. Kirsten Lund-Jurgensen,
will retire at the end of the year after 19 years at Pfizer, and
Executive Vice President, Strategy & Commercial Operations, Laurie
Olson, will retire effective January 1, 2019, after 32 years at Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of
October 9, 2018. The Company assumes no obligation to update
forward-looking statements contained in this release as a result of new
information or future events or developments.

This release contains forward-looking information about, among other
things, Pfizer’s anticipated future growth potential and its product
pipeline, including their potential benefits, that involves substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. Risks and
uncertainties include, among other things, the uncertainties inherent in
research and development, including the ability to meet anticipated
trial commencement and completion dates and regulatory submission dates,
as well as the possibility of unfavorable clinical trial results,
including unfavorable new clinical data and additional analyses of
existing clinical data; whether and when any drug applications may be
filed in any jurisdictions for any pipeline assets or new indications
for marketed products; whether and when regulatory authorities may
approve any such applications, which will depend on its assessment of
the benefit-risk profile suggested by the totality of the efficacy and
safety information submitted and, if approved, whether they will be
commercially successful; uncertainties regarding the commercial success
of Pfizer’s products and product candidates; other business effects,
including the effects of industry, market, economic, political or
regulatory conditions; and competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2017 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results,” as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at 


www.sec.gov

 and 

www.pfizer.com

.



Contact: 

Pfizer Inc.
Media:
Joan Campion
212-733-2798
or
Investor:
Charles Triano
212-733-3901